Cellectis (CLLS) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Cellectis is expected to announce quarterly earnings on August 5th, with analysts predicting a loss of $0.15 per share and revenue of $10.07 million.
• The company reported a loss of $0.18 per share last quarter, missing estimates, and had revenue of $12.03 million, below expectations.
• Barclays reduced the target price for Cellectis from $5.00 to $4.00 while maintaining an "overweight" rating on the stock.

Cellectis (NASDAQ:CLLS - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect Cellectis to post earnings of ($0.15) per share and revenue of $10.07 million for the quarter.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). Cellectis had a negative return on equity of 62.55% and a negative net margin of 114.82%. The business had revenue of $12.03 million during the quarter, compared to analyst estimates of $12.71 million. On average, analysts expect Cellectis to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cellectis Trading Up 17.5%

NASDAQ:CLLS traded up $0.44 during mid-day trading on Friday, reaching $2.95. The company's stock had a trading volume of 405,441 shares, compared to its average volume of 235,066. The company's fifty day simple moving average is $1.69 and its two-hundred day simple moving average is $1.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.67 and a quick ratio of 1.67. Cellectis has a twelve month low of $1.10 and a twelve month high of $3.10. The stock has a market cap of $163.96 million, a P/E ratio of -3.43 and a beta of 2.91.

Hedge Funds Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Acadian Asset Management LLC increased its stake in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) by 132.9% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 46,377 shares of the biotechnology company's stock after acquiring an additional 26,461 shares during the period. Acadian Asset Management LLC owned approximately 0.08% of Cellectis worth $55,000 at the end of the most recent reporting period. Institutional investors own 63.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Barclays decreased their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen lowered Cellectis from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.